Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation

Data from a retrospective cohort study of 142 patients with MPN and atrial fibrillation showed that myelofibrosis is associated with an increased risk of the composite outcome of cardiovascular death and arterial thromboembolism (SHR 2.70, 95% CI: 1.38-5.27). Traditional risk scores, such as CHA2DS2-VASC and HAS-BLED, were also noted to be poor predictors of the composite outcome (C-statistic 0.52, 95% CI: 0.43-0.62) and bleeding (C-statistic 0.49, 95% CI: 0.40-0.58).